Working… Menu

Evaluation of Clinical Endpoints of Two Diclofenac Sodium Gel 1%

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01456611
Recruitment Status : Completed
First Posted : October 21, 2011
Last Update Posted : July 12, 2012
Novum Pharmaceutical Research Services
Information provided by (Responsible Party):
Anchen Pharmaceuticals, Inc

Brief Summary:

The objective of this study is to evaluate the clinical equivalence and safety of the Test formulation of diclofenac sodium topical gel 1% (Anchen Pharmaceuticals, Inc.) compared to the marketed formulation Voltaren® Gel (diclofenac sodium topical gel) 1% (Novartis) in patients with osteoarthritis of the knee.

The efficacy of both the Test and Reference formulations will also be compared to the Placebo gel to determine Superiority.

Condition or disease Intervention/treatment Phase
Osteo Arthritis of the Knee Drug: Diclofenac Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 749 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Site Study to Evaluate the Clinical Equivalence of Diclofenac Sodium 1% Gel (Anchen Pharmaceuticals, Inc.) With Voltaren® Gel (Diclofenac Sodium Topical Gel) 1% (Novartis) in Patients With Osteoarthritis of the Knee
Study Start Date : September 2011
Actual Primary Completion Date : April 2012
Actual Study Completion Date : April 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arm Intervention/treatment
Experimental: Diclofenac Sodium Gel
Diclofenac sodium Topical Gel 1%
Drug: Diclofenac
Diclofenac Sodium Gel 1%

Active Comparator: Voltaren (R) Gel
Voltaren (R) Gel 1%
Drug: Diclofenac
Diclofenac Sodium Gel 1%

Placebo Comparator: Placebo
Placebo Topical Gel
Drug: Placebo
Placebo Topical Gel

Primary Outcome Measures :
  1. Mean Change from Baseline in WOMAC Pain Scale [ Time Frame: Baseline and Week 4 ]

Secondary Outcome Measures :
  1. Superiority of Test and Reference against Placebo in the Mean Change from baseline in the total WOMAC pain score. [ Time Frame: Baseline and Week 4 ]

    The superiority of treatment over the placebo will be concluded if the treatment's mean change from baseline in the total WOMAC pain score is statistically significantly greater (p<0.05) than that of the placebo in the ANCOVA based on the treatment and placebo results. The superiority of Test and Reference treatments over the placebo will be evaluated identically in a separate ANCOVA.

    The analyses will be conducted in the mITT population.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   35 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

1. Ambulatory Male and Non Pregnant Females 35 years and older diagnosed with osteoarthritis (according to the American College of Rheumatology Criteria) in one or both knees.

ACR Criteria includes, Knee Pain and at least 3 of the following:

  1. age ≥ 50
  2. stiffness lasting < 30 mins
  3. bony tenderness
  4. crepitus
  5. bony enlargement
  6. no palpable warmth

2. Symptom onset of > 6 Months prior to Screening for the target knee.

3. If female and of child-bearing potential, prepare to abstain from sexual intercourse or use a reliable method of contraception during the study (e.g., condom + spermicide, IUD, oral, transdermal, injected or implanted hormonal contraceptives).

4. Periarticular knee pain due to osteoarthritis (not bursitis, tendonitis etc) requiring the use of oral or topical treatments (NSAIDS or acetaminophen) for > 15 days in the 30 days prior to Screening.

5. Radiograph of the target knee within the previous year with a Grade 1, 2 or 3 disease based upon the Kellgren-Lawrence disease severity scale.

6. After a 7 day wash out of all pain medication has baseline pain on movement score of ≥ 50mm on a 100-mm Visual Analogue Scale for the target knee.

7. After a 7 day wash out of all pain medication has baseline WOMAC pain sub scale of ≥ 9 on a 5 question, 5 point (0 to 4) Likert scale for the target knee.

8. Willing and able to use only acetaminophen as rescue medication

9. Willing and able to comply with the study requirements.

Exclusion Criteria:

  1. Females who are pregnant, breast feeding, or planning a pregnancy
  2. Radiograph of the target knee within the previous year with a Grade 4 score on the Kellgren-Lawrence disease severity scale. 24
  3. History of osteoarthritis in the contralateral knee requiring medication (OTC or prescription) within 12 months of screening.
  4. After a 7 day wash out of all pain medication has baseline pain on movement score of ≥ 20mm on a 100-mm Visual Analogue Scale for the contralateral knee immediately prior to randomization.
  5. Known history of secondary osteoarthritis (e.g. congenital, traumatic, gouty arthritis) or rheumatoid arthritis.
  6. Known history of other chronic inflammatory diseases, (e.g.,colitis) or fibromyalgia.
  7. History of asthma, hypertension, myocardial infarction, thrombotic events, stroke, congestive heart failure, impaired renal function or liver disease.
  8. History of coronary artery bypass graft within 6 months of screening.
  9. Concomitant acetylsalicylic acid therapy other than a stable low dose used for cardiac prophylaxis (max 162mg daily) taken for at least 3 months prior to enrollment and maintained throughout the duration of the study.
  10. Use of warfarin or other anticoagulant therapy within 30 days of screening.
  11. Use of ACE inhibitors, cyclosporine, diuretics, lithium or methotrexate, within 30 days of screening or during the study.
  12. Known history of gastrointestinal bleeding or peptic ulcer disease.
  13. Abnormal screening clinical laboratory evaluations which the Investigator determines are clinically significant.
  14. Known allergy to aspirin or NSAIDs.
  15. Results from liver function tests that are more than two times the upper limit of the normal range at screening.
  16. Any other acute or chronic illness that in the opinion of the investigator could compromise the integrity of study data or place the Patient at risk by participating in the study.
  17. Concomitant use of corticosteroids (any formulation) or use within 30 days of study randomization.
  18. Receipt of any drug as part of a research study within 30 days prior to screening.
  19. Previous participation in this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01456611

  Show 57 Study Locations
Sponsors and Collaborators
Anchen Pharmaceuticals, Inc
Novum Pharmaceutical Research Services

Layout table for additonal information
Responsible Party: Anchen Pharmaceuticals, Inc Identifier: NCT01456611     History of Changes
Other Study ID Numbers: DCL-269
First Posted: October 21, 2011    Key Record Dates
Last Update Posted: July 12, 2012
Last Verified: July 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis, Knee
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action